CEL SCI Company Leadership
| CVM Stock | USD 4.78 0.12 2.45% |
CEL SCI employs about 10 people. The company is managed by 10 executives with a total tenure of roughly 152 years, averaging almost 15.0 years of service per executive, having 1.0 employees per reported executive. Analysis of CEL SCI's management performance can provide insight into the firm performance.
| Geert Kersten CEO Chief Executive Officer, Treasurer, Director |
| John Cipriano President Senior Vice President - Regulatory Affairs |
CEL SCI's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with CEL SCI's future performance. Based on our forecasts, it is anticipated that CEL will maintain a workforce of about 17380 employees by March 2026.CEL SCI Management Team Effectiveness
The company has Return on Asset of (0.5624) % which means that on every $100 spent on assets, it lost $0.5624. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.7632) %, meaning that it generated no profit with money invested by stockholders. CEL SCI's management efficiency ratios could be used to measure how well CEL SCI manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of February 2026, Return On Tangible Assets is likely to drop to -0.0009. In addition to that, Return On Capital Employed is likely to drop to -0.0013. At this time, CEL SCI's Intangibles To Total Assets are very stable compared to the past year.As of the 17th of February 2026, Common Stock Shares Outstanding is likely to grow to about 4.9 M, while Net Loss is likely to drop (30.6 M). The market capitalization of CEL SCI Corp is $40.19 Million. CEL SCI Corp shows 8.16 percent of its outstanding shares held by insiders and 8.85 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Shares in Circulation | First Issued 1985-12-31 | Previous Quarter 4.2 M | Current Value 8 M | Avarage Shares Outstanding 1.8 M | Quarterly Volatility 8.3 M |
CEL SCI Workforce Comparison
CEL SCI Corp is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 807. CEL SCI adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
CEL SCI Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CEL SCI insiders, such as employees or executives, is commonly permitted as long as it does not rely on CEL SCI's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CEL SCI insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-06-01 | 5.5 | 11 | 2 | 795,227 | 64,000 |
| 2022-09-01 | 2.0 | 4 | 2 | 4,837 | 64,000 |
| 2021-12-01 | 9.0 | 9 | 1 | 252,111 | 15,000 |
| 2021-06-01 | 13.0 | 13 | 1 | 1,876,683 | 10,000 |
| 2020-12-01 | 10.0 | 10 | 1 | 6,715 | 10,000 |
| 2019-09-01 | 3.5 | 7 | 2 | 9,483 | 16,000 |
| 2018-12-01 | 4.0 | 4 | 1 | 4,741 | 2,474 |
| 2018-06-01 | 6.4 | 32 | 5 | 1,834,204 | 697,016 |
| 2018-03-01 | 1.0 | 4 | 4 | 9,651 | 10,000 |
| 2017-12-01 | 8.0 | 8 | 1 | 151,129 | 0.00 |
| 2017-09-01 | 3.75 | 15 | 4 | 818,281 | 31,897 |
| 2015-06-01 | 12.0 | 12 | 1 | 5,404,900 | 0.00 |
| 2012-12-01 | 2.0 | 14 | 7 | 8,522,991 | 3,676,164 |
| 2011-12-01 | 1.4444 | 13 | 9 | 2,887,447 | 3,556,665 |
| 2011-03-01 | 4.0 | 4 | 1 | 19,697 | 100,000 |
| 2010-03-01 | 2.5 | 5 | 2 | 71,691 | 106,666 |
| 2009-12-01 | 0.6 | 3 | 5 | 13,797 | 1,657,000 |
| 2009-06-01 | 8.0 | 8 | 1 | 4,458,644 | 100,000 |
CEL SCI Notable Stakeholders
A CEL SCI stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CEL SCI often face trade-offs trying to please all of them. CEL SCI's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CEL SCI's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Geert Kersten | Chief Executive Officer, Treasurer, Director | Profile | |
| John Cipriano | Senior Vice President - Regulatory Affairs | Profile | |
| Patricia Prichep | Senior Vice President - Operations, Corporate Secretary | Profile | |
| Daniel Zimmerman | Senior Vice President - Research, Cellular Immunology | Profile | |
| Peter Young | Independent Director | Profile | |
| Robert Watson | Independent Director | Profile | |
| Bruno Baillavoine | Independent Director | Profile | |
| Giovanni MD | Acting Officer | Profile | |
| Geert Esq | Treasurer Officer | Profile | |
| Eyal Talor | Chief Scientific Officer | Profile |
About CEL SCI Management Performance
The success or failure of an entity such as CEL SCI Corp often depends on how effective the management is. CEL SCI management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CEL management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CEL management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Equity | (1.83) | (1.92) |
CEL SCI Workforce Analysis
Traditionally, organizations such as CEL SCI use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CEL SCI within its industry.CEL SCI Manpower Efficiency
Return on CEL SCI Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.5B | |
| Net Loss Per Executive | 2.5B | |
| Working Capital Per Employee | 646.6K | |
| Working Capital Per Executive | 646.6K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Will Biotechnology sector continue expanding? Could CEL diversify its offerings? Factors like these will boost the valuation of CEL SCI. Projected growth potential of CEL fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CEL SCI data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.27) | Revenue Per Share | Quarterly Revenue Growth (0.63) | Return On Assets | Return On Equity |
Understanding CEL SCI Corp requires distinguishing between market price and book value, where the latter reflects CEL's accounting equity. The concept of intrinsic value - what CEL SCI's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push CEL SCI's price substantially above or below its fundamental value.
It's important to distinguish between CEL SCI's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CEL SCI should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, CEL SCI's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.